What is Zacks Research's Estimate for Exelixis Q1 Earnings?

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Zacks Research lifted their Q1 2026 earnings per share estimates for shares of Exelixis in a research report issued to clients and investors on Tuesday, July 1st. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnings of $0.55 per share for the quarter, up from their prior estimate of $0.54. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis' Q2 2026 earnings at $0.61 EPS, FY2026 earnings at $2.54 EPS and Q1 2027 earnings at $0.67 EPS.

EXEL has been the topic of a number of other research reports. HC Wainwright raised their price target on Exelixis from $47.00 to $53.00 and gave the stock a "buy" rating in a research report on Monday. JMP Securities raised their price objective on shares of Exelixis from $47.00 to $50.00 and gave the stock a "market outperform" rating in a report on Monday, June 23rd. Morgan Stanley restated an "overweight" rating and issued a $47.00 price target (up from $40.00) on shares of Exelixis in a report on Wednesday, May 14th. Wells Fargo & Company reaffirmed a "market outperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Finally, Benchmark reissued a "neutral" rating on shares of Exelixis in a research note on Monday, June 23rd. Two analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of "Moderate Buy" and an average target price of $43.56.

Exelixis Price Performance

EXEL opened at $44.30 on Thursday. The stock has a market capitalization of $12.08 billion, a P/E ratio of 20.14, a price-to-earnings-growth ratio of 0.88 and a beta of 0.28. The company's 50 day simple moving average is $41.54 and its 200-day simple moving average is $37.51. Exelixis has a one year low of $21.82 and a one year high of $49.62.

Insider Buying and Selling

In related news, Director Jack L. Wyszomierski sold 7,535 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $43.09, for a total value of $324,683.15. Following the transaction, the director directly owned 358,882 shares in the company, valued at approximately $15,464,225.38. This represents a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Tomas J. Heyman sold 4,544 shares of the firm's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $44.29, for a total transaction of $201,253.76. Following the completion of the sale, the director directly owned 32,470 shares in the company, valued at $1,438,096.30. This represents a 12.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 458,113 shares of company stock valued at $21,024,817. Corporate insiders own 2.82% of the company's stock.

Institutional Trading of Exelixis

Institutional investors and hedge funds have recently made changes to their positions in the stock. Oppenheimer & Co. Inc. bought a new stake in shares of Exelixis in the 4th quarter valued at about $561,000. Proficio Capital Partners LLC purchased a new position in Exelixis during the 4th quarter valued at about $706,000. Fisher Asset Management LLC purchased a new stake in Exelixis in the 4th quarter worth approximately $1,493,000. Smartleaf Asset Management LLC lifted its stake in Exelixis by 958.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,942 shares of the biotechnology company's stock worth $99,000 after acquiring an additional 2,664 shares during the period. Finally, Schechter Investment Advisors LLC boosted its holdings in Exelixis by 6.3% in the fourth quarter. Schechter Investment Advisors LLC now owns 13,705 shares of the biotechnology company's stock valued at $456,000 after acquiring an additional 816 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.